, Volume 19, Issue 1, pp 1–9

Insulin aggregation in artificial delivery systems


  • W. D. Lougheed
    • The Hospital for Sick Children
  • H. Woulfe-Flanagan
    • Connaught Laboratories Limited
  • J. R. Clement
    • Connaught Laboratories Limited
  • A. M. Albisser
    • The Hospital for Sick Children
    • Biomedical ResearchThe Hospital for Sick Children
Review Articles

DOI: 10.1007/BF00258302

Cite this article as:
Lougheed, W.D., Woulfe-Flanagan, H., Clement, J.R. et al. Diabetologia (1980) 19: 1. doi:10.1007/BF00258302


Abrupt changes in flow path, motion, elevated temperatures, metal ion contamination, impure insulin formulations, CO2 diffusion, pH drop, dissimilar metal pump components, salt concentration, inappropriate diluents, elevated temperatures, refrigeration temperatures, processing, insulin heterogeneity, and buffering systems have been implicated to a greater or lesser extent in the plugging of insulin delivery devices. Before the rate at which insulin loses its biological activity in delivery systems can be assessed it is obvious that anti-aggregating diluents must be developed and subjected to long-term testing both in vitro and in vivo. Until such stable homogenous formulations are available the knowledge presented in this article will serve to decrease, but not eliminate, the problem of insulin aggregation in delivery systems. Further experiments are in progress and preliminary results [41] provide evidence that the problems cited are not without resolution. In this regard serum apparently contains factor(s) that promote the dissolution of insulin and prevent the formation of peptide aggregates in dilute solutions [41]. Many laboratories are now working to resolve the problem of insulin aggregation in artificial delivery devices.

Download to read the full article text

Copyright information

© Springer-Verlag 1980